JPRN-jRCT2031230432进行中（未招募）1 期
The phase I mass balance study to investigate the pharmacokinetics of OP-724 following a single dose of 14C-labeled OP-724 in healthy male volunteers.
Yuushi Haruyama0 个研究点目标入组 6 人开始时间: 2023年11月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 < 45age old（—）
- 性别
- Male
入选标准
- •1: Healthy Japanese male subjects.
- •2: Age at the time of obtaining written informed consent is >=18 to <45 years old.
- •3: Subjects who are capable of fully understanding the clinical trial and providing written informed consent.
排除标准
- •1: Subjects with any clinilcal abnormality assessed by the investigator or subinvestigator in laboratory tests, vital signs, or 12-lead ECG in eligibility testing.
- •2: Subjects with a QTcF of > 450 msec on a 12-lead ECG in the eligibility test.
- •3: Subjects who weighs < 50.0 kg in the eligibility test.
研究者
相似试验
已完成
不适用
A Phase 1 Study to Assess the Mass Balance, Excretion, and Pharmacokinetics of [14C]-GBT021601, an Oral Hemoglobin S Polymerization Inhibitor, in Healthy Participantssickle cell disease10038158sickle cell anemiaNL-OMON53865Global Blood Therapeutics, Inc.9
已完成
不适用
A Phase 1 Study to Assess the Mass Balance, Absolute Bioavailability, and Pharmacokinetics of 14C-ASTX029 in Healthy Volunteersadvanced solid tumorssolid tumorsNL-OMON51576Astex Pharmaceuticals, Inc.8
已完成
不适用
A Phase 1 Trial to Assess the Mass Balance, Absolute Bioavailability, and Pharmacokinetics of 14C ASTX660 in Healthy Volunteerssolid tumors, lymphomaadvanced solid tumors10024324lymphomaNL-OMON49455Astex Pharmaceuticals, Inc.8
尚未招募
不适用
A Phase 1 Trial to Assess the Mass Balance and Pharmacokinetics of 14C-Guadecitabine in Subjects with AML, MDS, or Solid Tumorsblood- and bone marrow cancer10024324NL-OMON46860Astex Pharmaceuticals, Inc6
进行中（未招募）
1 期
A study to investigate the uptake, distribution, breakdown and excretion of a single dose of [14C]-etripamil administered with a nasal spray in healthy volunteersParoxysmal supraventricular tachycardia (PSVT)EUCTR2019-004979-39-NLMilestone Pharmaceuticals Inc.8